Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech

Status Recruiting

Clinical Trial Summary

The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with neurodegenerative apraxia of speech (AOS).

Clinical Trial Description

Apraxia of Speech (AOS) is a disorder of speech motor planning and/or programming that affects the production of speech, characterized by slow speaking rate, abnormal prosody and distorted sound substitutions, additions, repetitions and prolongations, sometimes accompanied by groping, and trial and error articulatory movements. While AOS is commonly associated with vascular insults, it can be the predominant manifestation of neurodegenerative disease. Apraxia of speech can be the only manifestation of a neurodegenerative disorder. However, AOS very often co-occurs with aphasia, particularly a non-fluent aphasia (NFA) of the Broca's type; a language disorder, typically characterized by agrammatic, telegraphic or truncated spoken language, often accompanied by similar difficulties with written language. Patients with neurodegenerative AOS can have varying degrees of NFA, with the aphasia considered more severe than the AOS in some patients, but with the AOS dominant in others. It is extremely rare to have a patient that presents with NFA that does not also have AOS. Patients with isolated AOS can develop NFA over time, although in some patients the AOS remains isolated for as many as 8-10 years. Patients with AOS can also develop dysarthria and other non-speech motor symptoms, such as extrapyramidal features, postural instability, extra ocular eye movement abnormalities and limb apraxia. Cognitive impairment can also develop, although is rarely an early feature of the disease. The syndrome is progressive with many patients eventually becoming mute. Studies have shown that patients with neurodegenerative AOS can be pathologically heterogeneous, with some cases showing deposition of the microtubule associated protein tau, while others have deposition of the TAR DNA binding protein of 43kDa (TDP-43). Typical tau pathologies that are observed include corticobasal degeneration, progressive supranuclear palsy (PSP) and Pick's disease. Clinical features are currently unhelpful in predicting the underlying pathology in these cases, although there is a suggestion that cases with isolated or dominant AOS may be more likely to show tau pathology, particularly PSP. This project will be the first to assess longitudinal multi-modality neuroimaging in subjects with neurodegenerative AOS. It will allow us to assess all aspects of disease progression in these subjects, including changes on neuroimaging, speech and language, neurological, and neuropsychological assessments, to get a complete picture of dysfunction and progression in these subjects. This project will also be the first to apply DTI and the recently developed technique of resting state fMRI to the study of this disease. These techniques are of great current interest to the field and provide, for the first time, a way of assessing underlying functional and structural connectivity across the brain. Both techniques provide important information about how disease progresses through the brain tissue and have huge potential to be important future biomarkers of many different neurodegenerative diseases. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01818661
Study type	Interventional
Source	Mayo Clinic
Contact	Sarah Boland, CCRP
Phone	507-284-3863
Email	boland.sarah@mayo.edu
Status	Recruiting
Phase	Phase 4
Start date	July 1, 2018
Completion date	June 2028

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT04290988` - Circuitry Assessment and Reinforcement Training Effects on Recovery	N/A
Recruiting	`NCT04957537` - Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia	N/A
Completed	`NCT04045990` - Network Modulation in Alzheimer's Disease	N/A
Recruiting	`NCT05443633` - Enhancing Language Function in Aphasia	N/A
Completed	`NCT05860647` - Transmagnetic Stimulation Pilot in Primary Progressive Aphasia	N/A
Recruiting	`NCT03887481` - Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA	N/A
Completed	`NCT03728582` - Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy	N/A
Completed	`NCT01465360` - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center	N/A
Completed	`NCT02541097` - Preventing Language Decline in Dementia	N/A
Recruiting	`NCT00537004` - Language in Primary Progressive Aphasia
Recruiting	`NCT05741853` - Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia	N/A
Active, not recruiting	`NCT05742698` - Nabilone for Agitation in Frontotemporal Dementia	Phase 2
Completed	`NCT02439853` - Communication Bridge Speech Therapy Research Study	N/A
Completed	`NCT01623284` - PiB PET Scanning in Speech and Language Based Dementias	Phase 1
Completed	`NCT04726527` - Clinical Evaluation of Florbetapir in Primary Progressive Aphasia
Completed	`NCT03076671` - More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease	N/A
Completed	`NCT05537688` - Identification of Graphic Markers of Neurocognitive Disorders (MG)
Completed	`NCT05525377` - Better Living With Non-memory-led Dementia	N/A
Not yet recruiting	`NCT06191198` - Communication Bridge 3 Study	Phase 2
Completed	`NCT02928848` - Transcranial Direct Current Stimulation for Primary Progressive Aphasia	N/A